Novavax and IDT Partnership, page-14

Earlier this year it was made abundantly clear that CSL and Novavax is off the table.

As it stands IDT is the only company that has a facility to meet Novavax and government distribution requirements.

May 20th (Reuters) - CSL Ltd (CSL.AX) said on Thursday it does not have the capacity to simultaneously produce AstraZeneca (AZN.L) and Novavax Inc's (NVAX.O) COVID-19 vaccines after a local report said the U.S.-based firm was looking for an Australian manufacturing partner.

Australian biotech CSL is already under contract to locally make 50 million doses of the AstraZeneca vaccine, and is currently churning out more than a million doses a week. 

In January, the government ordered 51 million doses of Novavax's vaccine, with the Therapeutic Goods Administration (TGA) allowing the company to apply for provisional registration of the shot.

In an interview with the Sydney Morning Herald, Novavax's chief commercial officer, John Trizzino, said his company was looking for a local partner to make its vaccines and has had early conversations. 

Novavax did not immediately respond to a Reuters request for comment on its local production plans and who they have been in talks with.